4-<<(methylsulfonyl)oxy>methyl>-1-(4-methoxyphenyl)-2-pyrrolidinone | 148461-03-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-<<(methylsulfonyl)oxy>methyl>-1-(4-methoxyphenyl)-2-pyrrolidinone
• 英文别名: [1-(4-Methoxyphenyl)-5-oxopyrrolidin-3-yl]methyl methanesulfonate
• CAS: 148461-03-4
• 化学式: C₁₃H₁₇NO₅S
• 分子量: 299.348
• InChiKey: ILZJAOUJIUVPRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  584.0±25.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-<<(methylsulfonyl)oxy>methyl>-1-(4-methoxyphenyl)-2-pyrrolidinone 在 氢氧化钾 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[1-(4-Methoxyphenyl)-2-pyrrolidon-4-yl]methoxybenzoic acid
  参考文献：
  名称：

  Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses

  摘要：

  The synthesis of a series of 4[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits in vivo, are described. Among the compounds synthesized, 7e, 7g, 7h, 7i, 7k, 7r, 21, 23 and 29a b showed a potent inhibitory activity toward fatty-acid and sterol biosyntheses. Their IC(50)s were 4.4-6.8 x 10(-6) M and 6.6-9.8 x 10(-6) M, respectively. These activities were always superior to those of compounds I, II, III and Clinofibrate as references. The inhibitory activity toward the sterol biosynthesis of these compounds was inferior to that of Pravastatin. The reducing effects of the representative compounds (7e and 7l) toward plasma cholesterols and triglyceride were evaluated in Japanese white rabbits (30 and 100 mg/kg, po) and compared with those of Clinofibrate:and Pravastatin; The compounds showed a similar hypocholesterolemic effect to Pravastatin and a more potent hypotriglycemic effect than Clinofibrate and Pravastatin in this animal model. Thus, a dual,action of hypolipidemic effects was noted in 7e and 7l compared with the references.

  DOI：

  10.1016/0223-5234(94)90029-9
• 作为产物：
  描述：

  1-(4-甲氧基-苯基)-5-氧代-吡咯烷-3-羧酸 在 sodium tetrahydroborate 、 氯化亚砜 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 4-<<(methylsulfonyl)oxy>methyl>-1-(4-methoxyphenyl)-2-pyrrolidinone
  参考文献：
  名称：

  通过N-甲基化将杂环可逆单胺氧化酶-B灭活剂转化为不可逆灭活剂。

  摘要：

  3- [4-[（3-氯苯基）甲氧基]苯基] -5-[（甲基氨基）甲基] -2-恶唑烷酮（1）是一种仲胺，已知是一种有效的时间依赖性不可逆的单胺氧化酶B灭活剂（ MAO-B）。1的衍生物的伯胺类似物，以及相应的二氢呋喃酮和吡咯烷酮，已显示出是时间依赖性的，但可逆的MAO-B抑制剂。此处显示1的伯胺类似物是MAO-B的时间依赖性可逆抑制剂，相应的恶唑烷酮，二氢呋喃酮和吡咯烷酮的仲胺和叔胺类似物是MAO-B的时间依赖性不可逆抑制剂。可以通过升高温度来逆转导致与1形成不可逆酶加合物的反应。

  DOI：

  10.1021/jm00075a015

文献信息

• A 2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives
  作者：Sujay Basu、Dinesh A. Barawkar、Vidya Ramdas、Yogesh Waman、Meena Patel、Anil Panmand、Santosh Kumar、Sachin Thorat、Rajesh Bonagiri、Dilip Jadhav、Partha Mukhopadhyay、Vandna Prasad、B. Srinivasa Reddy、Arnab Goswami、Sandhya Chaturvedi、Suraj Menon、Azfar Quraishi、Indraneel Ghosh、Sushant Dusange、Shalini Paliwal、Abhay Kulkarni、Vikas Karande、Rhishikesh Thakre、Gaurav Bedse、Sreekanth Rouduri、Jayasagar Gundu、Venkata P. Palle、Anita Chugh、Kasim A. Mookhtiar

  DOI：10.1016/j.ejmech.2016.11.007

  日期：2017.2

  affinity adenosine receptor that functions by Gs mediated elevation of cAMP and subsequent downstream signaling. The receptor has been implicated in lung inflammatory disorders like COPD and asthma. Several potent and selective A2BAdoR antagonists have been reported in literature, however most of the compounds suffer from poor pharmacokinetic profile. Therefore, with the aim to identify novel, potent and

  甲2BA Dor是低亲和力腺苷受体，通过GS功能介导的cAMP的升高和随后的下游信号传导。该受体与肺炎性疾病如COPD和哮喘有关。在文献中已经报道了几种有效的和选择性的A 2B AdoR拮抗剂，但是大多数化合物的药代动力学特性较差。因此，为了鉴定具有改善的药代动力学特性的新颖，有效和选择性的A 2B AdoR拮抗剂，我们首先探索了更受约束的MRS-1754形式（4）。为了改善代谢稳定性，尝试了几种接头修饰，以取代黄嘌呤头基的C8位和末端苯环之间的酰胺接头以及不同的苯基或其他杂芳基。SAR优化导致鉴定了两种新型A 2B AdoR拮抗剂，即8- 1- [5-Oxo-1-（4-三氟甲基-苯基）-吡咯烷-3-基甲基] -1H-吡唑-4-基} -1 ，3-二丙基-黄嘌呤（31）和8-（1- 2-氧代-2- [4-（3-三氟甲基-苯基）-哌嗪-1-基]-乙基} -1H-吡唑-4-基）-1,3-二丙
• Thiazolidinedione derivatives or salts thereof and pharmaceutical
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US05990139A1

  公开（公告）日：1999-11-23

  This invention relates to a thiazolidinedione derivative represented by the following formula (1): ##STR1## wherein R.sup.1 and R.sup.2 individually represent H, a halogen atom, or a halogen-substituted or -unsubstituted lower alkyl or alkoxy group, and R.sup.1 and R.sup.2 may be coupled together to form a ring of an alkylenedioxy chain, X represents a nitrogen atom or a CH group, A represents a substituted or unsubstituted imidazolidinone, pyrrolidinone, imidazole or pyrazole ring, or a salt thereof; and a pharmaceutical composition containing the thiazolidinedione derivative or a salt thereof. The above compound has excellent blood sugar-lowering action and blood lipid-lowering action and is useful as a therapeutic agent for diabetes.

  本发明涉及一种由以下式（1）表示的噻唑烷二酮衍生物：##STR1## 其中，R.sup.1和R.sup.2分别表示H、卤原子或卤代或未卤代的低碳基或低碳氧基，R.sup.1和R.sup.2可以耦合在一起形成烷二氧基链的环，X表示氮原子或CH基，A表示取代或未取代的咪唑烷酮、吡咯烷酮、咪唑或吡唑环或其盐；以及含有噻唑烷二酮衍生物或其盐的制药组合物。上述化合物具有优异的降血糖作用和降血脂作用，并且可用作糖尿病治疗剂。
• US5990139A
  申请人：——

  公开号：US5990139A

  公开（公告）日：1999-11-23